William Blair analyst Brandon Vazquez has maintained their bullish stance on PEN stock, giving a Buy rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight Penumbra’s promising advancements in medical technology. The recent presentation of STORM-PE data at the TCT 2025 conference demonstrated significant improvements in patient outcomes, particularly in the immediate unloading of patients with a safety profile comparable to anticoagulation alone. This marks a substantial advancement over previous technologies, which were hindered by bleeding risks. The data suggest that more intermediate-high-risk PE patients will soon be offered mechanical thrombectomy, potentially increasing the adoption rate in a large addressable market.
Furthermore, the STORM-PE study showcased impressive results, including a statistically significant reduction in RV/LV ratio, zero transfusion rates, and a 100% successful procedure rate, all achieved by surgeons new to the Lightning technology. These outcomes, coupled with a lower composite adverse event rate compared to anticoagulation alone, indicate a strong safety and efficacy profile. With additional quality of life benefits expected to be presented soon, Vazquez believes that Penumbra’s technology will continue to gain traction, justifying a Buy rating.
In another report released today, Needham also reiterated a Buy rating on the stock with a $326.00 price target.